BeyondSpring Inc BYSI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024
-
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024
-
BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respiratory Medicine
-
BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin
-
SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications
Trading Information
- Previous Close Price
- $2.05
- Day Range
- $2.05–2.20
- 52-Week Range
- $0.65–4.00
- Bid/Ask
- $2.08 / $2.19
- Market Cap
- $88.66 Mil
- Volume/Avg
- 31,535 / 24,353
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 45.79
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 36
Comparables
Valuation
|
Metric
|
BYSI
|
ZURA
|
6976
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 1.66 | 2.05 |
Price/Sales | 45.79 | — | 1,185.36 |
Price/Cash Flow | — | — | — |
Price/Earnings
BYSI
ZURA
6976
Financial Strength
|
Metric
|
BYSI
|
ZURA
|
6976
|
|---|---|---|---|
Quick Ratio | 1.75 | 12.50 | 59.63 |
Current Ratio | 1.82 | 12.57 | 60.01 |
Interest Coverage | — | — | −94.19 |
Quick Ratio
BYSI
ZURA
6976
Profitability
|
Metric
|
BYSI
|
ZURA
|
6976
|
|---|---|---|---|
Return on Assets (Normalized) | −61.33% | −20.26% | −5.20% |
Return on Equity (Normalized) | — | −29.67% | −5.51% |
Return on Invested Capital (Normalized) | — | −30.68% | −8.30% |
Return on Assets
BYSI
ZURA
6976
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Mzyxxyjwz | Nyrk | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Jkbhbgx | Rprcwr | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Gqtjbcsn | Qwkyw | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Vpbmrrzh | Htwkrlt | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Tdsfdmr | Bydyf | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Bpbjmsg | Sdlvv | $28.1 Bil | |||
| Moderna Inc
MRNA
| Pqjxhpkf | Mftch | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Dmbcsbjw | Mvzb | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Xdcwvkltt | Cklxzf | $13.4 Bil | |||
| Incyte Corp
INCY
| Glnpmydzq | Jjrntc | $12.7 Bil |
United States